Tuesday, 23 Apr 2019

You are here

SynBioSe: Combo Rituximab and Belimumab Succeeds in Severe Refractory Lupus

One of the driving pathogenic mechanisms in systemic lupus erythematosus (SLE) is the generation of immune complexes capable of inducing netosis (NET formation) and NET-derived DNA that may be an amplifying autoantigen and give rise to anti-nuclear autoantibodies (ANAs). 

Researchers from Leiden University Medical Center in The Netherlands sought to target autoreactive plasma cells and interfere with immune complex formation and netosis in SLE by treating patients with a combination of rituximab (RTX) and belimumab (BLM).

The SynBioSe study was a 2A, open-label, single arm proof-of-concept study that treated 16 SLE patients who had severe, refractory disease despite aggressive immunosuppressive treatments.  All had active disease with a mean SLEDAi of 18 and the majority had lupus nephritis and were on mycophenolate. 

Patients underwent CD20-mediated B-cell depletion with rituximab (1000 mg on days 0 and 14) followed by  belimumab 10 mg/kg (on days 28, 42, 56, and every 4 weeks thereafter). The protocol called for all to have their glucocorticoids (60 to 7.5 mg/day) and mycophenolate tapered (to zero). The study endpoints at 24 weeks examined SLEDAI scores, immunologic effects (autoantibodies, NET formation, etc) and safety outcomes. 

As expected, they demonstrated a significant rise in BlyS levels following RTX therapy, which was subsequently diminished with belimumab treatment. RTX + BLM led to specific reductions in ANAs, autoantibodies and dimunution of NET formation.

Significant clinical improvement was also seen with a low lupus disease activity state achieved in 10 patients, renal responses in 11 patients and concomitant immunosuppressive medication (MMF) tapered in 14 of the 16 patients.

The trial was a highlight presentation from EULAR 2017 meeting and is now published in the Journal of Autoimmunity.

Combination therapy with RTX + BLM appears to effectively reduce autoantibodies and excessive NET formation, with significant clinical benefits in severe refractory SLE patients.  Future studies with this intriguing combination are warranted.

ClinicalTrials.gov NCT02284984.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

EULAR 2019 Update to Lupus Management

The goal of SLE treatment is remission or low disease activity and flare prevention. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. Glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent). Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can be tailored to the clinical scenarios and may allow for tapering or discontinuation of GC.

Mortality Risk Factors in Systemic Sclerosis

A French cohort study of 625 systemic sclerosis (SStc) patients has found a significantly increased mortality risk that can be predicted by common clinical variables.

In addition to a multicenter prospective study, investigators performed a metanalysis on SSc standarized mortality ratios (SMR) and hazard ratios of prognosis factors.

Better Tests Ahead in Lupus

The advent of "big data" and "-omics" technologies offers hope that clinicians will soon have better diagnostics for systemic lupus erythematosus, rheumatologists here were told.

GCA Relapse Risk High with Steroids

Prior to the introduction of tocilizumab to manage giant cell arteritis (GCA), glucocorticoids (GC) have been the mainstay of therapy, but has been limited by relapses in disease. A recent metanalysis shows that relapses occur in nearly half of patients and are related to the duration of therapy rather than the initial dose of GC.

A literature review found 34 studies (2,505 patients) from 8 RCTs of GCA patients only treated with GC.

Presenting Features of Early SLE

What clinical features best identify early systemic lupus erythematosus (SLE) patients from mimics?  A multicenter, multinational study aimed to evaluate manifestations at disease onset and to compare early SLE manifestations to those of diseases mimicking SLE.